This was due to our decision to apply L1 regulation in order to obtain the simplest model for the purpose of helping clinicians determine which of their patients with T2D would most likely benefit from adding GLP-1 M as the second-line medication. Here, GLP1R is linked to type 2 diabetes mellitus.